SinoMab BioScience Ltd (HKG: 3681) announced positive readouts from a Phase I bridging study in China evaluating route of administration conversion for SM17, a novel first-in-class humanized IgG4-κ monoclonal antibody targeting the interleukin-25 (IL-25) receptor (IL-17RB). The study supports formulation optimization for this type 2 inflammatory modulator, which inhibits ILC2 and Th2 cell signaling and downregulates IL-4, IL-5, and IL-13 production.
Clinical Study Overview
Parameter
Detail
Study Phase
Phase I (bridging study)
Objective
Route of administration conversion evaluation
Geography
China
Product
SM17 (humanized IgG4-κ monoclonal antibody)
Target
IL-25 receptor (IL-17RB) – type 2 immune alarmin pathway
First-in-class IL-25 pathway inhibition vs. IL-4/IL-13 (dupilumab) or IL-5 (mepolizumab)
Strategic Context & Competitive Position
Factor
Implication
Type 2 Inflammation Market
$20+ billion globally (atopic dermatitis, asthma, biologics); IL-25 represents upstream “alarmin” target with potential for broader efficacy
First-in-Class Position
Only IL-25 receptor antibody in clinical development; addresses ILC2-driven inflammation not targeted by current biologics
Route Conversion Rationale
Bridging study supports subcutaneous or alternative formulation vs. IV – improves patient convenience and commercial scalability
Competitive Landscape
Dupilumab (IL-4R, $10B+), tralokinumab (IL-13), tezepelumab (TSLP); SM17’s IL-25 upstream positioning may offer combination or superior monotherapy potential
China Development Strategy
Bridging study enables NMPA Phase II/III initiation; potential for China-first approval given unmet need in severe atopic dermatitis
Development Timeline: Phase II initiation Q3 2026 (atopic dermatitis or asthma); global partnership discussions anticipated 2027 with Phase Ib data package
Commercial Potential: Peak sales $500 million–1 billion if approved in multiple type 2 indications with differentiated efficacy vs. IL-4/IL-13 blockade
Forward‑Looking Statements This brief contains forward‑looking statements regarding route of administration optimization, Phase II indication selection, and clinical development progress for SM17. Actual results may differ due to formulation scale-up challenges, competitive dynamics with established type 2 inflammation biologics, and regulatory pathway decisions for first-in-class antibodies.-Fineline Info & Tech
By Fineline Cube